The aim of the present clinical positron emission tomography study was to examine if the 5-HTT is a common target, both for tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). Serotonin transporter (5-HTT) occupancy was estimated during treatment with TCA, SSRI and mirtazapine in 20 patients in remission from depression. The patients were recruited from out-patient units and deemed as responders to antidepressive treatment. The radioligand [11C]MADAM was used to determine the 5-HTT binding potential. The mean 5-HTT occupancy was 67% (range 28-86%). There was no significant difference in 5-HTT occupancy between TCA (n=5) and SSRI (n=14). 5-HTT affinity correlated with the recommended clinical dose. Mirtazapine did not occupy the serotonin transporter. The results support that TCAs and SSRIs have a shared mechanism of action by inhibition of 5-HTT. © 2012 CINP.
CITATION STYLE
Lundberg, J., Tiger, M., Landén, M., Halldin, C., & Farde, L. (2012). Serotonin transporter occupancy with TCAs and SSRIs: A PET study in patients with major depressive disorder. International Journal of Neuropsychopharmacology, 15(8), 1167–1172. https://doi.org/10.1017/S1461145711001945
Mendeley helps you to discover research relevant for your work.